Clinical Trials Logo

Substance-Related Disorders clinical trials

View clinical trials related to Substance-Related Disorders.

Filter by:

NCT ID: NCT00447733 Completed - Anxiety Disorders Clinical Trials

Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders

ROP
Start date: March 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether Integrated Treatment is effective in the treatment of anxiety and/or depression with co-occurring substance use disorders.

NCT ID: NCT00438685 Completed - Depressive Disorder Clinical Trials

Outpatient Adolescent Treatment for Comorbid Substance Use and Internalizing Disorders

Start date: October 2004
Phase: Phase 1
Study type: Interventional

Adolescent substance abuse results in significant negative outcomes and extraordinary costs for youths, their families, communities, and society. Moreover, rates of psychiatric comorbidity among substance abusing youth range from 25% up to 82%, and youths with a dual diagnosis have worse outcomes and are more than twice as costly to treat than their counterparts with no comorbidity. This project was a pilot test of a new treatment, OPTION-A, which was adapted from Multisystemic Therapist (MST) and other evidence-based interventions to specifically treat youth presenting for outpatient treatment of comorbid substance use and internalizing disorders. The project was a randomized controlled pilot trial comparing the experimental treatment to usual services in the community.

NCT ID: NCT00437840 Completed - Clinical trials for Substance Dependence

A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809

Start date: March 20, 2007
Phase: Phase 1
Study type: Interventional

GSK598809 is being developed to facilitate overcoming an addiction to nicotine and to help people stop smoking. This study will investigate if GSK598809 is safe and tolerated in people who smoke and will also look at blood levels of GSK598809 and nicotine.

NCT ID: NCT00437632 Completed - Clinical trials for Substance Dependence

Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809

Start date: March 1, 2007
Phase: Phase 1
Study type: Interventional

GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders. This study will evaluate the safety, tolerability and pharmacokinetics of repeat doses of GSK598809 in healthy volunteers.

NCT ID: NCT00430482 Completed - Clinical trials for Substance Dependence

Stress, Distress Intolerance, and Drug Dependence

Start date: June 2005
Phase: N/A
Study type: Interventional

This study is designed to evaluate the relative efficacy of a novel treatment (CBT-IC) versus a standard individual drug-counseling treatment. The novel treatment emphasizes exposure to emotional cues for drug use as part of a comprehensive, yet brief, treatment strategy. These treatments are delivered to opiate-dependent, often poly-substance dependent, individuals in a comprehensive methadone maintenance program who have failed to respond adequately to current treatments.

NCT ID: NCT00419029 Completed - Depression Clinical Trials

Motivational Interviewing to Engage Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans in Mental Health Treatment

Start date: September 2007
Phase: N/A
Study type: Interventional

The goal of this randomized controlled trial is to evaluate the efficacy of telephone-administered motivational interviewing (TAMI) to enhance VA mental health treatment engagement among veterans of Operations Enduring Freedom (OEF) and Iraqi Freedom (OIF) who screen positive for mental health disorders on telephone assessment. The investigators will evaluate whether TAMI results in improved mental health treatment engagement, decreased mental health symptoms and increased quality of life among OEF/OIF veterans with mental health disorders. The long-term aim of this study is to conduct rapid assessment and intervention to prevent chronic mental illness and associated disability among our newest generation of veterans.

NCT ID: NCT00407732 Completed - Hepatitis C Clinical Trials

Overcoming Psychiatric Barriers to the Treatment of Hepatitis C

Start date: January 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to develop and evaluate a 9-month psychosocial intervention that will assist patients with hepatitis C in overcoming barriers that prevent them from becoming appropriate candidates for interferon therapy.

NCT ID: NCT00399763 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

Start date: September 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to find out whether atomoxetine (also called Strattera) helps teenagers (12-19) with Attention Deficit Hyperactivity Disorder (ADHD) and drug/alcohol problems.

NCT ID: NCT00383045 Completed - Opiate Dependence Clinical Trials

HIV Risk Reduction and Drug Abuse Treatment in Malaysia

Start date: April 2003
Phase: Phase 2
Study type: Interventional

A randomized clinical trial comparing drug abuse and HIV risk reduction counseling (DC-HIV) alone, DC-HIV combined with naltrexone maintenance, and DC-HIV combined with buprenorphine maintenance for the treatment of heroin addicts in Malaysia.

NCT ID: NCT00375102 Completed - Substance Abuse Clinical Trials

Acupuncture and the Relaxation Response for Substance Abuse

Start date: November 2006
Phase: Phase 2/Phase 3
Study type: Interventional

This one-year pilot study has two specific aims: 1. to determine the feasibility of conducting a randomized controlled trial of acupuncture and the relaxation response for substance abuse among homeless veterans who are in a domiciliary care program, and 2. to collect and analyze pilot data to estimate the effect size for planning a future larger study to fully test the hypothesis of the effectiveness of acupuncture and the RR in reducing cravings for substances (alcohol and drugs), and the corollary effects on quality of life.